NPI: 1730566027 · KOSCIUSKO, MS 39090 · Critical Access Hospital · NPI assigned 05/06/2015
Authorized official DUCKETT, GREGORY controls 20+ related entities in our dataset. Read more
| Authorized Official | DUCKETT, GREGORY (SR VP/ CLO) |
| Parent Organization | BAPTIST MEMORIAL HEALTH CARE CORP. |
| NPI Enumeration Date | 05/06/2015 |
Other providers sharing the same authorized official: DUCKETT, GREGORY
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 35,779 | $1.27M |
| 2019 | 34,594 | $1.32M |
| 2020 | 27,152 | $1.03M |
| 2021 | 32,464 | $1.17M |
| 2022 | 51,773 | $1.33M |
| 2023 | 44,002 | $1.53M |
| 2024 | 26,028 | $1.13M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 15,884 | 12,693 | $1.98M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 8,698 | 6,900 | $1.35M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4,700 | 3,755 | $846K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7,399 | 6,106 | $564K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4,733 | 3,672 | $350K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 8,032 | 5,849 | $287K |
| 71045 | Radiologic examination, chest; single view | 8,257 | 6,208 | $281K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 6,574 | 5,301 | $262K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 7,986 | 6,143 | $254K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 20,790 | 8,177 | $222K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1,581 | 1,256 | $200K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2,577 | 1,664 | $198K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2,418 | 1,803 | $193K |
| 70450 | Computed tomography, head or brain; without contrast material | 2,601 | 2,071 | $176K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 8,208 | 5,989 | $144K |
| G0378 | Hospital observation service, per hour | 489 | 370 | $135K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2,290 | 1,447 | $128K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 4,948 | 3,838 | $117K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 7,500 | 5,938 | $105K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3,017 | 2,649 | $102K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3,532 | 2,625 | $81K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 16,541 | 11,585 | $76K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 424 | 348 | $73K |
| 83880 | 3,488 | 2,542 | $71K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 341 | 292 | $64K |
| 80053 | Comprehensive metabolic panel | 9,786 | 7,214 | $61K |
| 84484 | 7,286 | 4,492 | $48K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3,841 | 3,319 | $47K |
| 80048 | Basic metabolic panel (calcium, ionized) | 6,902 | 5,063 | $38K |
| 36415 | Collection of venous blood by venipuncture | 16,456 | 11,334 | $29K |
| A9270 | Non-covered item or service | 2,770 | 1,947 | $26K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 132 | 64 | $17K |
| 81001 | 8,675 | 6,767 | $17K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,565 | 1,216 | $17K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 98 | 81 | $17K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 208 | 184 | $14K |
| 81025 | 2,407 | 1,979 | $14K | |
| 87807 | 1,399 | 1,128 | $14K | |
| 71046 | Radiologic examination, chest; 2 views | 395 | 298 | $13K |
| 83735 | 2,668 | 1,941 | $10K | |
| 74018 | 211 | 179 | $9K | |
| 82553 | 1,059 | 829 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1,686 | 1,347 | $8K |
| 83690 | 1,949 | 1,485 | $8K | |
| 82550 | 1,422 | 1,081 | $7K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 144 | 116 | $7K |
| 73560 | 155 | 139 | $7K | |
| 83605 | 1,195 | 857 | $6K | |
| 36600 | 279 | 183 | $6K | |
| 85610 | 2,162 | 1,670 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 4,611 | 3,577 | $5K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 87 | 81 | $4K |
| 82803 | 287 | 187 | $4K | |
| 87040 | 689 | 309 | $4K | |
| 80305 | 469 | 365 | $4K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 3,437 | 2,422 | $3K |
| 87634 | 60 | 55 | $3K | |
| 73610 | 76 | 53 | $3K | |
| 87400 | 256 | 171 | $2K | |
| 73030 | 56 | 48 | $2K | |
| 80061 | Lipid panel | 207 | 166 | $2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 31 | 22 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | 340 | 267 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 2,541 | 1,936 | $2K |
| 87430 | 174 | 117 | $2K | |
| 85379 | 334 | 256 | $2K | |
| 82150 | 527 | 378 | $2K | |
| 85027 | 429 | 286 | $1K | |
| 73630 | 28 | 25 | $1K | |
| 87186 | 336 | 238 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 23 | 19 | $1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 55 | 52 | $1K |
| 86900 | 19 | 12 | $876.74 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 13 | 12 | $782.21 |
| 51702 | 16 | 12 | $776.70 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 21 | 15 | $693.40 |
| 87581 | 16 | 14 | $564.52 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 2,821 | 2,102 | $520.42 |
| 96376 | 151 | 76 | $505.08 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 349 | 268 | $477.80 |
| 0001A | 34 | 32 | $434.93 | |
| 96367 | 12 | 12 | $433.04 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1,494 | 1,184 | $397.17 |
| 85730 | 168 | 132 | $352.04 | |
| 0002A | 15 | 15 | $333.03 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 47 | 29 | $332.68 |
| 86901 | 19 | 12 | $265.02 | |
| 86756 | 25 | 18 | $263.27 | |
| J2704 | Injection, propofol, 10 mg | 423 | 296 | $224.39 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 146 | 79 | $206.80 |
| 84443 | Thyroid stimulating hormone (TSH) | 18 | 13 | $195.30 |
| 84703 | 25 | 20 | $174.21 | |
| 85007 | 52 | 43 | $136.57 | |
| 82009 | 18 | 13 | $70.28 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 41 | 24 | $57.28 |
| 80047 | 17 | 12 | $52.71 | |
| 86140 | 13 | 13 | $46.69 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 656 | 423 | $43.79 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 92 | 71 | $39.69 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 1,466 | 1,177 | $29.48 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 186 | 123 | $18.81 |
| J1940 | Injection, furosemide, up to 20 mg | 114 | 66 | $10.39 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 28 | 26 | $10.22 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 78 | 49 | $9.26 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 13 | 12 | $2.73 |
| C9113 | Injection, pantoprazole sodium, per vial | 13 | 12 | $2.71 |
| 84145 | 39 | 35 | $1.98 | |
| J7510 | Prednisolone oral, per 5 mg | 61 | 55 | $0.16 |
| 94664 | 46 | 34 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 37 | 28 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 23 | 12 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 29 | 26 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 27 | 12 | $0.00 |